The Pfizer scientists and the LNP developers knew TEN years ago that LNP & mRNA shots did not stay in the arm.

Their 2015 study shows they knew how to control the distribution of the LNP mRNA formula. No kidding.

The Pfizer scientists Kariko and Wiseman and the LNP developers knew TEN years ago that the formulation did not stay in the arm.

Below are screenshots of my research work from 2022 and 2023 that synthesize their 2015 study on the biodistribution of mRNA and LNPs. Yes, 2015.

They - the lipid LNP developers and the mRNA developers not only knew LNP formulations and LNP mRNA formulations would distribute through the body, but they also knew how to keep it from distributing further than the arm; no kidding.

mRNA LNP formulation distribution into the body can also be seen in the 2020 Wistar Han Rat Study sponsored by Acuitas Therapeutics (Pfizer and Moderna LNP manufacturer).

This information and my work on the lipids is used in litigation in Germany and Australia and investigations here in the U.S. They knew long ago, and their studies do not allow them to hide. I put my LNP work on my SubStack for use in litigation with permission so that I know where it is utilized and can help if needed. My SubStacks on the lipids can be found throughout my SubStack, including these studies on biodistribution.

This LNP mRNA formulation "systemic distribution" was described ten years ago by the study co-authored by Kariko and Weissman. It was also around this same period that Kariko and Weissmen approached Peter Cullis (co-developer of the lipids used in both Moderna and Pfizer Covid mRNA “vaccines” in 2015, seeking a way to keep the formulation from the liver. There was a reason the soon-to-be COVID-19 vaccine developers were asking for a lipid or LNP formulation that would not accumulate in the liver.

After all, we should not explain away any amount of poison in the body, much less where it goes in the body. We should certainly express our concern when it is "systemically delivered," as the mRNA vaccine and LNP developers explain in their 2015 study below.

According to the developers in their own work, the formulation does not stay locally unless it is injected superficially.

The study says that when injected into the muscle, the formulation is "trafficked systemically." In reading multiple studies on liposomal and lipid carriers, the lipids or LNP formulation is easily able to accumulate in the liver due to the cells that easily uptake the lipids. Hence, it easily translates in the liver, but can translate in the lungs and accumulate in other areas of the body, as seen in the 2015 study co-authored by Kariko, Weissman, and several Aqutas Therapeutics (Covid-19 vaccine LNP developer) scientists.

The Aquitas Therapeutics sponsored 2020 Wistar Han Rat Study, and the recent 2025 study, which shows that the LNPs and mRNA formulation distributes systemically, as it was designed to do.

The late Dr. Arne Burkardt found foreign material described in his histopathology studies of deceased Covid-19 mRNA vaccinated individuals. He considered some of this material could be an accumulation of the LNP lipid and other vaccine foreign bodies. One such structure was found in the lung.

This is interesting as the vaccine developers and LNP developers describe the LNP mRNA formula found in the lung for 8 days after injection in their 2015 study. But as you may know, very few autopsies were performed on those who passed away during the pandemic, and as such, many opportunities to investigate evidence of the destructive path of the vaccine components (including the lipids) were lost.

LNP involvement in damaged tissues can be stained for/tested, and there is a way to find where the LNPs travel in the body. I have been asking pathologists worldwide to perform this test since 2022. I approached them with my request in 2023 when writing to Dr. Burkhardt with the help of Dr. Tess Lawrie.

We should all know the truth that in-depth pathology alone can provide.

The below study excerpts from the 2015 study co-authored by Kariko, Weissman, and several Acquitas therapeutics scientists (mRNA vaccine and LNP developers) explain that upon injection through various routes, the LNP/mRNA formulation is found in the lung, the spleen, the eye socket, abdomen, and describe the below systemic distribution.

It states,

"Intravenous and intraperitoneal and to a lesser extent intramuscular and intratracheal deliveries led to trafficking of mRNA-LNPs systemically resulting in active translation of the mRNA in the liver for 1–4 days." "When mRNA-LNPs were injected intramuscularly and intratracheally, similar to intravenous and intraperitoneal deliveries, a large portion of the luciferase activity was detectable in the liver, demonstrating systemic spread of the nanoparticles. “

Cont… “Also similar to intravenous and intraperitoneal deliveries, the high levels of protein produced in the liver occurred over a short duration, with the majority of translation ceasing at day 2 post-injection (Fig. 2). Interestingly, significant bioluminescent signal could be measured in the lungs and muscles, as well, with the latter lasting for up to 8 days post injection." "We believe that systemic delivery results in high luminescent signals due to the large number of potential target cells and fast turnover in the liver. Similarly, for i.m. and s.c. deliveries, the high luminescence is likely due to the large number of cells that take up the mRNA-LNPs and also the efficient uptake and translation of the particles."

The above is just the tip of the iceberg.

With LNP lipid platforms, anywhere the “wanted” materials go, so do the “unwanted” materials: Anywhere the lipids go, proteins from the bloodstream go, and that means free floating spike as well, so not only can the LNPs loaded with mRNA go throughout the body into the cells, but they can also bring in contamination and proteins that are not wanted, including bringing free-floating spike where the LNPs go. The LNP co-developer Peter Cullis wrote on this aspect of the LNP biomolecular corona and accumulation of proteins in 2020, just a couple of months before the mRNA vaccine roll-out. The links to my work are below, and the data and references are found within.

Here are some screenshots of my research also found in Substack and Trialsites News:

There are a total of ten posts from my 109-page executive brief on the LNPs.

You can find ample information in the pages I have provided. Let me know if I can help in any way.

Cody’s mom

Heather Hudson

* The writer is not a doctor, and even though guest writers may be medical professionals, the information in this document and this publication is not a substitution for personal or individual medical care, treatment, medical advice, or diagnosis. Always contact your own medical care provider for individual care and consultation. This document does not diagnose medical conditions, treat illnesses, or prescribe medicine or drugs. Any information contained in this document, related links, or attachments is not a substitute for seeking adequate medical care, diagnosis, and/or treatment from your own medical doctor.